Insulin Glargine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Insulin Glargine
- Pharmacist Assessment Report
- Insulin Glargine: From Type 2 Diabetes Mellitus to Autoimmune Oophoritis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Insulin Glargine: From Type 2 Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin glargine is a long-acting basal insulin, originally used to treat type 1 and type 2 diabetes mellitus. The TxGNN model predicts it may be effective for autoimmune oophoritis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (other recorded indications: type 1 diabetes mellitus, diabetic ketoacidosis) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 0.9988 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Note: No approved-indication text was available in the India licence records, so the original indication could not be taken from them.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, insulin glargine is a long-acting insulin analogue used for basal glucose control, and its efficacy in diabetes is well established.
The link to autoimmune oophoritis is most likely indirect. Autoimmune oophoritis often occurs together with autoimmune polyendocrine syndromes, which can include type 1 diabetes. The high score therefore probably reflects proximity in the disease network, not a therapeutic effect of insulin on ovarian autoimmunity. No evidence suggests insulin treats the ovarian condition itself.
Other top-ranked predictions show similar patterns. Several (thiamine-responsive dysfunction syndrome, stiff person syndrome, focal stiff limb syndrome) are linked through a shared diabetes phenotype or anti-GAD autoimmunity. Insulin would only manage comorbid diabetes, not the underlying disease. Localized lipodystrophies are likely confounded by the fact that insulin injection itself can cause lipodystrophy at injection sites. Pancreatic agenesis (rank 6) is mechanistically coherent, since insulin replacement is standard care for the resulting diabetes, but this is arguably an extension of the existing diabetes indication rather than true repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for autoimmune oophoritis.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 120850 | Lantus 100IU/ml Solution for Injection | Vial of 10 ml solution for injection | Not specified |
| 94480 | Glaritus 100IU/ml Injection | Vial of 10 ml injection | Not specified |
| 214942 | Toujeo 300U/ml Cartridge (1.5 ml each) | Packet of 3 cartridges | Not specified |
| 25967 | Basalog One 100IU/ml Injection | Pre-filled pen of 3 ml injection | Not specified |
| 25951 | Basaglar 100IU/ml Kwikpen | Pre-filled pen of 3 ml solution for injection | Not specified |
There are 20 valid single-ingredient registrations in total, held by Sanofi India, Wockhardt, Biocon, Lupin and Cipla. All are injectable presentations (vials, cartridges, pre-filled pens and syringes).
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.
Drug Interactions: The interaction screening identified 352 interacting drugs. Most of the 20 listed are of moderate severity:
- Other glucose-lowering agents (metformin, pioglitazone, alogliptin, albiglutide): moderate; additive glucose-lowering effects.
- Sympathomimetics and bronchodilators (epinephrine, phenylephrine, pseudoephedrine, salbutamol, formoterol): moderate.
- Corticosteroids (hydrocortisone): moderate; topical corticosteroids (hydrocortisone, alclometasone) are minor.
- Others: acebutolol, acetazolamide, doxycycline, ethinylestradiol, estradiol, hydrochlorothiazide, alpelisib and ethanol, all moderate.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for autoimmune oophoritis rests on a high model score alone, with no clinical trials or publications and a probable association-based explanation (shared autoimmune and diabetes context) rather than a therapeutic one. Insulin glargine is well established and widely marketed in India for diabetes, but this does not support the new indication.
To proceed, the following is needed:
- Evidence that insulin or insulin glargine has a direct benefit in autoimmune oophoritis (preclinical, observational or clinical)
- Mechanism of action data
- Package insert warnings and contraindications for a safety assessment
- A clear separation of true repurposing from management of comorbid diabetes, for example in pancreatic agenesis, where insulin is already standard care for the resulting diabetes
- Route and formulation compatibility assessment for the new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.